ELVR in PH Patients With Severe Emphysema

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study. An improvement of objective parameters may also have a prognostic significance

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bronchioscopic Lung Volume Reduction (BLVR)

NCT02415478

Chronic Obstructive Pulmonary Disease (COPD)

UNKNOWN

Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

NCT01357460

Hereditary Emphysema (Alpha 1-antitrypsin Deficiency)

TERMINATED NA

To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves

NCT02022683

COPD Heterogeneous Emphysema

COMPLETED NA

Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement

NCT05204875

Emphysema

UNKNOWN

Lung Volume Reduction Via Coils in Patients With COPD

NCT02246569

Chronic Obstructive Pulmonary Disease (COPD)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

So far there is no treatment of COPD in addition to the established treatment of concomitant PH. Administration of PH-specific medication outside of clinical trials is not recommended in new guidelines for PH of the ERS/ESC. The influence of endobronchial valve implantation on the PH has not been studied in detail. The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study. An improvement of objective parameters may also have a prognostic significance

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Pulmonary Emphysema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* signed patient consent form
* men and women \>30 years
* Clinically indicated endoscopic lung volume reduction
* Pulmonary hypertension according to Group 3.1 of the Dana Point classification
* Severe pulmonary emphysema
* FEV1 \<45%
* RV\> 150%
* TLC\> 100%
* Maximum of medical therapy according to GOLD
* heterogeneous emphysema
* Detected in the HR-CT
* Confirmation of the heterogeneity of emphysema by computer-assisted quantification (YACTA ®)
* stable COPD
* No exacerbation in the last 8 weeks
* Cortisone dose \<20 mg prednisolone equivalent
* Non-or ex-smoker
* Nicotine abstinence\> 4 months
* Actual CoHb \<2.5%
* Diagnosis of pulmonary hypertension (PH), invasively diagnosed by right heart catheterization:
* Mean pulmonary arterial pressure (mPAP)\> 25 mmHg
* Pulmonary capillary wedge pressure (PCWP) \<15 mmHg
* Pulmonary vascular resistance (PVR)\> 320 dyne \* sec \* cm-5

Exclusion Criteria

* PH of Group 1, 2, 4, 5 of the Dana Point Classification
* Previous operations
* s/p Lung resection (lobectomy / pneumonectomy)
* s/p endoscopic lung volume resection
* significant bronchiectasis
* Sputum volume\> 4 tablespoons / day
* Severe cardiac comorbidities:
* s/p myocardial infarction in the last 6 weeks
* Congestive heart failure
* Cardiomyopathy with highly impaired LVF
* Clopidogrel in long-term medication
* Respiratory insufficiency: PaCO2 mmHg at rest\> 55
* current pregnancy

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No